

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 August 2003 (14.08.2003)

(10) International Publication Number  
**WO 03/066575 A1**

- (51) International Patent Classification<sup>2</sup>: C07C 231/12. (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US03/03437
- (22) International Filing Date: 4 February 2003 (04.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/354,777 5 February 2002 (05.02.2002) US
- (71) Applicant: WYETH [US/US]; a corporation of the State of Delaware, Five Giralda Farms, Madison, NJ 07940 (US).
- (72) Inventors: DUNCAN, Scott, Mason; 10 Stone Crest Circle, Madison, Wisconsin 53717 (US). OSUMA, Augustine, Tobi; 4640 Shoreview Drive, Canton, MI 48188 (US). DAIGNEAULT, Sylvain; 201 Peupliers Laval-Sur-Le-Lac, Quebec H7R1G6 (CA). BERNATCHEZ, Michel; 3990 Gouin East, Montreal H1H1C6 (CA).
- (74) Agents: MORAN, Daniel, B. et al.; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940 (US).
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066575 A1

(54) Title: PROCESS FOR THE SYNTHESIS OF N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS

(57) Abstract: The invention claimed herein provides a process to oxidize N- (5-alkoxy-2-methyl-4-nitrophenyl) acetamides to N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids using potassium permanganate in the presence of magnesium sulfate in aqueous sulfolane or aqueous pyridine.

**PROCESS FOR THE SYNTHESIS OF N-ACYL-2-AMINO-4-ALKOXY-5-NITROBENZOIC ACIDS**

5

**BACKGROUND OF THE INVENTION**

**FIELD OF THE INVENTION**

This invention relates to a process for the synthesis of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids by the oxidation of N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides using potassium permanganate in aqueous solvent mixtures.

**DESCRIPTION OF THE PRIOR ART**

Potassium permanganate is a widely used reagent for the oxidation of benzylic carbon atoms to the corresponding carboxylic acid. However, oxidations do not always work well for substrates having limited water solubility and furthermore, potassium permanganate has limited solubility in organic solvents. The problem with insolubility has been addressed to some extent by the use of biphasic conditions employing water and either benzene or a hydrocarbon solvent as the organic phase, or, alternatively by using a phase transfer catalyst. Unfortunately, many organic compounds or substrates have poor solubility in either water or hydrocarbon solvents. The limited contact between the oxidant and the substrate results in long reaction times, poor yields and the formation of contaminants which make purification difficult. Further, many typical organic solvents cannot be used as a co-solvent with potassium permanganate because being such a potent oxidant, the organic solvents are themselves oxidized, leading to diverse and complicated reaction mixtures. The use of a phase transfer catalyst can lead to further purification problems.

The N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids that are obtained according to the process of this invention are useful intermediates to produce 3-cyanoquinolines. The 3-cyano quinolines are used in the synthesis, as described in U.S. Pat. No. 6,002,008 of certain protein tyrosine kinase (PTK) inhibitors useful for

the treatment of cancer. The toluidines that are required to produce the desired N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids have very poor solubility in water. The problem of poor water solubility contributes to incomplete reactions and variable yields when performing the oxidation in water alone with potassium permanganate

5       as the oxidizing agent in the presence of magnesium sulfate. The accelerated decomposition of potassium permanganate, under aqueous conditions requires a very large excess of the oxidant resulting in large volumes of inorganic waste. Additionally, the low solubility of both the substrate and the oxidant in water contribute to the inefficiency of the total process by requiring high dilutions (>40:1).

10       It is also known that certain substrates, which include derivatives of toluidine such as N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides, can catalyze the decomposition of potassium permanganate. As mentioned above, solubility and decomposition problems contribute to the need for a large excess of potassium permanganate. Also, isolating and solving problems of potassium permanganate

15       oxidations are difficult because of the subtleties of the equilibrium between the various oxidation states of manganese.

The N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides used as the oxidation substrates are prepared with acetic anhydride using conditions well described in the art (e.g., A.Ono in Chem. Ind.(London), 4, 130, 1982). As described, adding N-(5-  
20       alkoxy-2-methyl-4-nitrophenyl)acetamides as a solid to an aqueous mixture of the potassium permanganate and magnesium sulfate at about 80-90°C followed by heating the reaction mixture to reflux for 1 hour further required adding additional potassium permanganate and magnesium sulfate as necessary at 30 minute intervals to fully oxidize the N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides.

25       Typically, 4 to 5 equivalents of the oxidant are necessary under these conditions. The yield of the oxidation under totally aqueous conditions is however improved by adding the substrate as a hot slurry in water. However, the disadvantage to this procedure becomes apparent on larger scale when one needs to prepare the substrate as a hot slurry in water followed by adding the slurry to the aqueous

30       potassium permanganate.

It is, therefore, an object of the present invention to provide a new process for the preparation of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids which avoids the solubility problems associated with potassium permanganate in organic solvents and


5 to additionally solve the problem of needing a large excess of potassium permanganate.

Thus, there is a need in the art for a process which overcomes the problems of solubility and the need for excess potassium permanganate when oxidizing, in particular, toluidines.

10 Those and other objects of the present invention will become more apparent from the detailed description thereof set forth below.

#### SUMMARY OF THE INVENTION

15 The present invention provides a new process for the preparation of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids having the structural formula



20


wherein:

$\text{R}_3$  is  $-\text{OR}$  and

$\text{R}$  is alkyl of 1 to 3 carbon atoms;

which process comprises oxidizing N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides

25 having the formula



where


$\text{R}_3$  is  $-\text{OR}$ ; and

5 R is alkyl of 1 to 3 carbon atoms;

with potassium permanganate in an aqueous solvent mixture to afford N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids after acidification. The oxidation is generally carried out in solution in a solvent system comprising water and a cosolvent, normally an organic cosolvent.

10

The invention also provides a process for the manufacture of a compound having the formula I



15 wherein:

X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl

20 of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio

- of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms,
- 5 alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;
- $R_3$  is  $-OR$ ;
- $R$  is alkyl of 1 to 3 carbon atoms;
- $n$  is 0-1;
- 10  $Y$  is  $-NH-$ ,  $-O-$ ,  $-S-$ , or  $-NR_{10}-$ ;
- $R_{10}$  is alkyl of 1-6 carbon atoms;
- $R_2$  is
- $$\begin{array}{c} R_8 \\ \diagdown \\ C = C \\ \diagup \\ R_8 \end{array} \begin{array}{c} CONH^- \\ | \\ R_8 \end{array}$$
- in which each  $R_8$  is independently selected from hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxylalkyl of 1-6 carbon atoms, alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, and bromo; or a pharmaceutically acceptable salt thereof;
- 15
- 20
- 25
- which process comprises
- (a) preparing an N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid compound by the process provided therefor by the invention and
- (b) converting the N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid compound so prepared into a compound having formula I as defined and illustrated above or an acid addition salt thereof.  $X$  is preferably optionally substituted phenyl, particularly 3-chloro-4-fluorophenyl. The symbol  $n$  is preferably 0.  $Y$  is preferably  $-NH-$ .  $R_3$  and
- 30

RO – are preferably ethoxy. R<sub>2</sub> is preferably R<sub>8</sub> –CH = CH – CO –NH - (in which R<sub>8</sub> is as defined above), R<sub>2</sub> being advantageously 4-(dimethylamino)but-2-enoyl – NH –

The compound of formula I is preferably N-{ 4-[(3-chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-but enamide.

5

The conversion of part (b) comprises using the acetyl amino group at the 2-position and the carboxy group at the 1- position of the 2-(acetyl amino)-4-alkoxy-5-nitrobenzoic acid as a precursor for a group of the formula II



- 10 (wherein X, Y and n are as defined above) and using the nitro group at the 5-position of the 2-(acetyl amino)-4-alkoxy-5-nitrobenzoic acid as precursor for R<sub>2</sub>. The formation of the group of the formula II may be carried out by cleaving the acetyl group from the acetyl amino group, preferably under basic or acidic conditions, for instance, by a basic solvolysis, more preferably by alkaline alcoholysis, e.g. with
- 15 KOH/MeOH, and using the resultant amino group and the carboxy group as precursor for a group of the formula II. The conversion of the amino group and carboxy group to the group of formula II may be carried out by known methods, for instance, by methods disclosed in US Patent 6,002,008. The conversion of the nitro group into R<sub>2</sub> may be carried out by reducing the nitro group to form an amino group
- 20 and subjecting the amino group to amide formation by reaction with a carboxylic acid having the formula (R<sub>8</sub>)<sub>2</sub> –C = C R<sub>8</sub> – COOH (in which each R<sub>8</sub> is as defined above) or a reactive derivative thereof, for instance the acid chloride having the formula (R<sub>8</sub>)<sub>2</sub> –C = C R<sub>8</sub> – COCl. The conversion of the nitro group into R<sub>2</sub> may be carried out by methods known *per se*, for instance methods disclosed in US Patent
- 25 6,002,008. The formation of the group of the formula II is preferably carried out before the conversion of the nitro group into R<sub>2</sub>. Thus part (b) preferably comprises
  - (i) cleavage of the acyl group of the N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid compound so as to form a 2-amino-4-(C<sub>1</sub> – C<sub>3</sub> alkoxy)-5-nitrobenzoic acid;
  - (ii) converting the 2-amino-4-(C<sub>1</sub> – C<sub>3</sub> alkoxy)-5-nitrobenzoic acid into a nitro
- 30 compound having formula I as illustrated above in which R, X, Y and n are as defined above and R<sub>2</sub> is nitro;

- (iii) reducing this nitro compound so as to form an amino compound having formula I as illustrated above in which R, X, Y and n are as defined above and R<sub>2</sub> is amino; and
- (iv) subjecting this amino compound to amide formation by reaction with a carboxylic acid having the formula (R<sub>8</sub>)<sub>2</sub>—C = C R<sub>8</sub> — COOH (in which each R<sub>8</sub> is as defined above) or a reactive derivative thereof.

The pharmaceutically acceptable salts are those derived from such organic and inorganic acids as: acetic, lactic, citric, tartaric, succinic, maleic, malonic, gluconic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known as acceptable acids.

#### DETAILED DESCRIPTION OF THE INVENTION

- In accordance with this invention the production of N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids is provided in high yield and purity by a process which comprises:
- oxidizing N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides with potassium permanganate in the presence of magnesium sulfate in aqueous sulfolane (5-45% water) or aqueous pyridine at about 80 to 110 °C;
- acidifying the reaction mixture and collecting the product.

Preferred according to the process of the invention is a sulfolane:water volume ratio of about 19:1 to 1:1 v/v.

Preferred according to the process of the invention is a magnesium sulfate to potassium permanganate ratio of about 1:4 equivalents of magnesium sulfate to about 3:3.5 molar equivalents of potassium permanganate.

Preferred is acidifying the reaction mixture to a pH of about 2 to 6 and more preferably about 2 to 4.

Preferred is a reaction temperature of about 80-90°C.

Surprisingly, the use of sulfolane as a co-solvent in the oxidation of N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides allowed the reaction concentration to be more than doubled (20:1), minimized the amount of oxidant (3 to 3.5 molar equivalents) vs. 4 to 5 previously used under totally aqueous conditions and

5 dramatically increasing the yield from 30 to 50% to at least 68 to 71% and further reducing the amount of inorganic waste. The use of sulfolane simplifies the isolation process by avoiding extraction procedures. A further advantage is that the process is very reproducible. A preferred procedure is to add solid potassium permanganate to a hot solution of N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides in the presence of

10 magnesium sulfate in aqueous sulfolane at 80 to 90 °C. An additional advantage of this procedure is that the oxidation may optionally be performed by adding the N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamides as a sulfolane solution to the oxidizing mixture of potassium permanganate in water. The isolation of the product is accomplished by filtering the reaction mixture to remove inorganics, followed by

15 diluting the filtrate with water and acidifying the reaction mixture to about pH 2 to 4. The product precipitates and is collected by filtration. Similar results are obtained using aqueous pyridine as the solvent. Preferred cosolvents are sulfolane and pyridine.

In order to facilitate a further understanding of the invention, the following  
20 non-limiting examples illustrate the process of the present invention.

Example 1

2-acetylaminio-4-ethoxy-5-nitrobenzoic acid

A 5-L Morton flask equipped with an overhead stirrer and thermocouple is charged  
25 with N-(5-ethoxy-2-methyl-4-nitro-phenyl)-acetamide(46 g, 193 mmol), aq. sulfolane (95:5 v/v, 500 mL) and water (200 mL). The reaction mixture is heated to 90 °C and then magnesium sulfate ( $MgSO_4$ ) (46g, 382 mmol) and water (200 mL) are added to the reaction mixture. The potassium permanganate ( $KMnO_4$ ) (105 g, 670 mmol) is added in 15-g portions every 15 minutes until the reaction is complete by HPLC  
30 [>95%]. Retention time  $T_r$  of N-(5-ethoxy-2-methyl-4-nitro-phenyl)-acetamide is 10.7 min and  $T_r$  of 2-acetylaminio-4-ethoxy-5-nitro-benzoic acid is 12.4 min in a 65:35 mixture of  $CH_3CN$  with 0.1 % trifluoroacetic acid (TFA): $H_2O$  run isocratically at 1.0

mL/ min with a Phenomenex Prodigy 5 ODS column (250 X 4.6 mm). The hot solution (>80 °C) is filtered thru diatomaceous earth (6" diameter and 1" thick) and the filter cake ( $\text{MnO}_2$ ) is rinsed with hot water (>80 °C, 3 X 200 mL). While stirring the filtrate, 10% HCl is added until the pH is adjusted to about 2 to 4 and stirring of the suspension continued while cooling to ambient temperature (15 to 25 °C). The suspension is filtered with a fritted funnel (medium) and the filter cake is washed with water (3 X 200 mL). The cake is dried to constant weight under vacuum (50 mm Hg) at 40 to 50 °C. This procedure provides product of high purity in good yield (36.5g, 70% yield, >98% purity by NMR integration).  $^1\text{H}$  NMR (300 MHz, DMSO-d<sub>6</sub>)  
11.5 (br s, 1H), 8.52 (s, 1H), 8.50 (s, 1H), 4.22 (q,  $J=7$  Hz, 2H), 2.21 (s, 3H), 1.40 (t,  $J=7$  Hz, 3H)

Example 2

2-acetylamino-4-ethoxy-5-nitrobenzoic acid

15 A 500 mL Morton flask equipped with an overhead stirrer and thermocouple is charged with N-(5-ethoxy-2-methyl-4-nitro-phenyl)-acetamide(3 g, 12.5 mmol) and aq. sulfolane (95:5 v/v, 35 mL). While stirring is added  $\text{MgSO}_4$  (5 g, 41.5 mmol) and water (15 mL). The reaction mixture is heated to 90-95 °C and 125 mL (31.2 mmol, 2.4 eq) of a 0.25M aqueous solution of  $\text{KMnO}_4$  is added at a rate to control  
20 exothermic foaming. The reaction is complete in about 15 to 20 minutes by HPLC [ $>95\%$ ]. Retention time  $T_r$  of N-(5-ethoxy-2-methyl-4-nitro-phenyl)-acetamide is 10.7 min and  $T_r$  of 2-acetylamino-4-ethoxy-5-nitro-benzoic acid is 12.4 min in a 65:35 mixture of  $\text{CH}_3\text{CN}$  with 0.1 % TFA:H<sub>2</sub>O run isocratically at 1.0 mL/ min with a Phenomenex Prodigy 5 ODS column (250 X 4.6 mm). However, should the reaction  
25 be incomplete, as shown by HPLC system above, additional portions of the  $\text{KMnO}_4$  (25 mL, 6.25 mmol) are added at 15-20 minute intervals and completion monitored by HPLC as above. The hot solution (>80 °C) is filtered through diatomaceous earth (6" diameter and 1" thick) and the filter cake ( $\text{MnO}_2$ ) is rinsed with hot water (>80 °C, 3 X 200 mL). While stirring the filtrate, 10% HCl is added until the pH is adjusted to  
30 about 2 to 4 and stirring of the suspension continued while cooling to ambient temperature (15 to 25 °C). The suspension is filtered with a fritted funnel (medium) and the filter cake is washed with water (3 X 200 mL). The cake is dried to constant

weight under vacuum (50 mm Hg) at 40 to 50 °C. This procedure provides product of high purity in good yield; 2.4 g, 71%, purity >98% by NMR integration or by HPLC.

5


Example 3  
2-acetylamino-4-ethoxy-5-nitrobenzoic acid

10

In a 5-L multi-neck flask, equipped with mechanical stirrer, thermometer and condenser is charged with water (1500 mL) followed by MgSO<sub>4</sub> (67 g). To the resulting solution is added pyridine (500 mL) and then N-(5-ethoxy-2-methyl-4-nitro-phenyl)-acetamide (50 g) over 5 min. The suspension is heated to 85 °C and the 15 resulting solution is charged with KMnO<sub>4</sub> (150.0 g) over 20 min until the reaction is complete by HPLC [> 95%]. Retention time Tr of N-(5-ethoxy-2-methyl-4-nitro-phenyl)-acetamide is 7.5 min and Tr of 2-acetylamino-4-ethoxy-5-nitrobenzoic acid is 8.5 min) in a 40:60 mixture of CH<sub>3</sub>CN with 0.1%H<sub>3</sub>PO<sub>4</sub>:H<sub>2</sub>O run isocratically at 1.0 mL/min with a Phenomenex Luna C8 column (150 x 4.6 mm). Upon completion, the 20 hot mixture (80 to 85 °C) is filtered on a Buchner (20 cm diameter). The filter cake (MnO<sub>2</sub>) is washed with hot water (850 mL). The filtrates are combined, cooled to 30 °C and treated with conc. HCl (125 mL) to pH = 6. The resulting suspension is stirred at 30 °C for 30 min and the product is collected on a Buchner funnel (20 cm diameter). The cake is suspended in water (500 mL) and treated with conc. HCl (11 25 mL) to pH = 1.5. The product is collected on a Buchner funnel (16 cm diameter) and washed with water (100 mL) followed by acetone (50 mL). The cake is dried to constant weight under vacuum (10 mm Hg) at 65 °C. This procedure provides product of high purity in good yield (38.5 g, 68.4%, 98.7% purity by HPLC). <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>): 11.5 (br s, 1H), 8.52 (s, 1H), 8.50 (s, 1H), 4.22 (q, j=7 Hz, 2H), 30 2.21 (s, 3H), 1.40 (t, j=7 Hz, 3H)

**What is claimed:**


- 5    1. A process for the preparation of a N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid compound having the structural formula



wherein:

$\text{R}_3$  is  $-\text{OR}$ ; and

- 10   R is alkyl of 1 to 3 carbon atoms;  
 which process comprises:  
 oxidizing a N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamide compound having the structural formula



- 15   where  
 $\text{R}_3$  is  $-\text{OR}$ ; and  
 R is alkyl of 1 to 3 carbon atoms;  
 with potassium permanganate in solution in a solvent system comprising water and a cosolvent in the presence of magnesium sulfate.

2. The process of claim 1 wherein potassium permanganate is present in the amount of about 3 to 3.5 molar equivalents.

3. The process of claim 1 wherein the solvent system is aqueous sulfolane.

5

4. The process of claim 3 wherein the sulfolane to water volume ratio is present at about 19:1 to 1:1.

5. The process of claim 1 wherein the solvent system is aqueous pyridine.

10


6. The process of claim 1 wherein the ratio of magnesium sulfate to potassium permanganate is present in the amount of about 1:4 equivalents of magnesium sulfate to about 3:3.5 molar equivalents of potassium permanganate.

15 7. The process of claim 1 wherein the reaction temperature is about 80 to 110°C.

8. The process of claim 7 wherein the reaction temperature is about 80-90°C.

9. A process for the preparation of a N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid

20 compound having the structural formula




wherein:

R<sub>3</sub> is -OR; and

25 R is alkyl of 1 to 3 carbon atoms;

which process comprises the steps:

- a.) heating to 80-90°C an aqueous solution, containing sulfolane as a cosolvent, and a N-(5-alkoxy-2-methyl-4-nitrophenyl)acetamide compound having the structural formula



5


wherein:

R<sub>3</sub> is -OR; and

R is alkyl of 1 to 3 carbon atoms;

- 10 b.) adding magnesium sulfate to the aqueous solution;  
 c.) adding sufficient potassium permanganate to the aqueous solution to complete oxidation;  
 d.) filtering the hot solution;  
 e.) acidifying the solution to a pH of about 2 to 4 with cooling and collecting the N-  
 15 acyl-2-amino-4-alkoxy-5-nitrobenzoic acid.

10. The process of claim 9 wherein potassium permanganate is present in the amount of about 3 to 3.5 molar equivalents.
- 20 11. The process of claim 9 wherein the sulfolane to water volume ratio is present at about 19:1 to 1:1.
12. The process of claim 9 wherein the ratio of magnesium sulfate to potassium permanganate is present in the amount of about 1:4 equivalents of magnesium sulfate to about 3:3.5 molar equivalents of potassium permanganate.
- 25 13. A process for the manufacture of a compound having the formula I



wherein:

- 5      X is cycloalkyl of 3 to 7 carbon atoms, which may be optionally substituted with one or more alkyl of 1 to 6 carbon atom groups; or is a pyridinyl, pyrimidinyl, or phenyl ring; wherein the pyridinyl, pyrimidinyl, or phenyl ring may be optionally mono-, di-, or tri-substituted with a substituent selected from the group consisting of halogen, alkyl of 1-6 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, azido, hydroxyalkyl of 1-6 carbon atoms, halomethyl, alkoxymethyl of 2-7 carbon atoms, alkanoyloxymethyl of 2-7 carbon atoms, alkoxy of 1-6 carbon atoms, alkylthio of 1-6 carbon atoms, hydroxy, trifluoromethyl, cyano, nitro, carboxy, carboalkoxy of 2-7 carbon atoms, carboalkyl of 2-7 carbon atoms, phenoxy, phenyl, thiophenoxy, benzoyl, benzyl, amino, alkylamino of 1-6 carbon atoms, dialkylamino of 2 to 12 carbon atoms, phenylamino, benzylamino, alkanoylamino of 1-6 carbon atoms,
- 10     alkenoylamino of 3-8 carbon atoms, alkynoylamino of 3-8 carbon atoms, and benzoylamino;
- 15     R<sub>3</sub> is -OR;


R is alkyl of 1 to 3 carbon atoms;

n is 0-1;

- 20     Y is -NH-, -O-, -S-, or -NR<sub>10</sub>- ;

R<sub>10</sub> is alkyl of 1-6 carbon atoms;

R<sub>2</sub> is



- 25     in which each R<sub>8</sub> is independently selected from hydrogen, alkyl of 1-6 carbon atoms, aminoalkyl of 1-6 carbon atoms, N-alkylaminoalkyl of 2-9 carbon atoms, N,N-dialkylaminoalkyl of 3-12 carbon atoms, N-cycloalkylaminoalkyl of 4-12 carbon atoms, N-cycloalkyl-N-alkylaminoalkyl of 5-18 carbon atoms, N,N-

- dicycloalkylaminoalkyl of 7-18 carbon atoms, morpholino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, piperidino-N-alkyl wherein the alkyl group is 1-6 carbon atoms, N-alkyl-piperidino-N-alkyl wherein either alkyl group is 1-6 carbon atoms, azacycloalkyl-N-alkyl of 3-11 carbon atoms, hydroxyalkyl of 1-6 carbon atoms,
- 5 alkoxyalkyl of 2-8 carbon atoms, carboxy, carboalkoxy of 1-6 carbon atoms, phenyl, carboalkyl of 2-7 carbon atoms, chloro, fluoro, and bromo; or a pharmaceutically acceptable salt thereof;
- which process comprises:
- 10 (a) preparing a N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid compound by the process of any one of claims 1 to 12 and
- (b) converting the N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid compound so prepared into a compound having formula I as defined and illustrated above or an acid addition salt thereof.
- 15 14. A process as claimed in claim 13, in which part (b) of the process comprises
- (i) cleavage of the acyl group of the N-acyl-2-amino-4-alkoxy-5-nitrobenzoic acid compound so as to form a 2-amino-4-(C<sub>1</sub> – C<sub>3</sub> alkoxy)-5-nitrobenzoic acid;
- (ii) converting the resultant 2-amino-4-(C<sub>1</sub> – C<sub>3</sub> alkoxy)-5-nitrobenzoic acid into a
- 20 nitro compound having formula I as illustrated in claim 13 in which R, X, Y and n are as defined in claim 13 and R<sub>2</sub> is nitro;
- (iii) reducing this nitro compound so as to form an amino compound having formula I as illustrated in claim 13 in which R, X, Y and n are as defined in claim 13 and R<sub>2</sub> is amino; and
- 25 (iv) subjecting this amino compound to amide formation by reaction with a carboxylic acid having the formula (R<sub>8</sub>)<sub>2</sub>C = C R<sub>8</sub> – COOH (in which each R<sub>8</sub> is as defined in claim 13) or a reactive derivative thereof.
15. A process as claimed in claim 13 or 14 carried out so as to prepare N-{ 4-[(3-
- 30 chloro-4-fluorophenyl)amino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide.

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US 03/03437

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07C231/12 C07D215/54 C07D215/56

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BEILSTEIN Data, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 68186 A (AMERICAN CYANAMIDE) 20 September 2001 (2001-09-20) claims; example 399	13-15
A	-----	1,9

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

5 June 2003

Date of mailing of the international search report

17/06/2003

Name and mailing address of the ISA

European Patent Office, P.O. Box 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Fax. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Zervas, B

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Search Report No	PCT/US 03/03437
-----------------------------------	-----------------

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
WO 0168186	A 20-09-2001	AU	4545201 A	24-09-2001	
		BR	0109165 A	22-04-2003	
		EP	1263503 A2	11-12-2002	
		NO	20024356 A	12-11-2002	
		WO	0168186 A2	20-09-2001	